Poseida Therapeutics Inc (PSTX)
3.19
-0.16
(-4.63%)
USD |
NASDAQ |
May 17, 16:00
3.19
0.00 (0.00%)
After-Hours: 20:00
Poseida Therapeutics Research and Development Expense (Quarterly): 42.92M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 42.92M |
| December 31, 2023 | 42.04M |
| September 30, 2023 | 37.48M |
| June 30, 2023 | 39.19M |
| March 31, 2023 | 38.05M |
| December 31, 2022 | 33.90M |
| September 30, 2022 | 35.14M |
| June 30, 2022 | 35.01M |
| March 31, 2022 | 48.85M |
| December 31, 2021 | 39.11M |
| September 30, 2021 | 32.52M |
| Date | Value |
|---|---|
| June 30, 2021 | 36.01M |
| March 31, 2021 | 29.10M |
| December 31, 2020 | 27.88M |
| September 30, 2020 | 27.02M |
| June 30, 2020 | 25.21M |
| March 31, 2020 | 23.41M |
| December 31, 2019 | 19.20M |
| September 30, 2019 | 15.70M |
| June 30, 2019 | 16.88M |
| March 31, 2019 | 8.613M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
15.70M
Minimum
Sep 2019
48.85M
Maximum
Mar 2022
32.23M
Average
34.46M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biomea Fusion Inc | 33.78M |
| Cartesian Therapeutics Inc | 9.738M |
| Lantern Pharma Inc | 4.251M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |